ASCENDIS PHARMA A/S - AMERICAN DEPOSITARY SHARES

Ascendis Pharma to Participate in the BofA Securities 2023 Health Care Conference

03 май 2023 15:15:00 Источник Nasdaq GlobeNewswire

U.S. Food & Drug Administration Issues Complete Response Letter for TransCon™ PTH in Hypoparathyroidism

01 май 2023 06:00:00 Источник Nasdaq GlobeNewswire

Ascendis Pharma Reports First Quarter 2023 Financial Results

27 апр 2023 15:01:00 Источник Nasdaq GlobeNewswire

Ascendis Pharma Announces First Quarter 2023 Financial Results and Business Update Conference Call on April 27

13 апр 2023 07:30:00 Источник Nasdaq GlobeNewswire

Ascendis Pharma’s Initial Dose Escalation Results from the Ongoing Phase 1/2 Trial of TransCon™ IL-2 β/γ Accepted for Online Publication at ASCO 2023

03 апр 2023 06:05:00 Источник Nasdaq GlobeNewswire

Ascendis Pharma Provides Update on Regulatory Reviews of TransCon PTH™ in Hypoparathyroidism

03 апр 2023 06:00:00 Источник Nasdaq GlobeNewswire

Ascendis Pharma to Participate in the Oppenheimer 33rd Annual Healthcare Conference

10 мар 2023 07:00:00 Источник Nasdaq GlobeNewswire

Ascendis Pharma Reports Full Year 2022 Results

16 фев 2023 15:01:00 Источник Nasdaq GlobeNewswire

Ascendis Pharma Announces Full Year 2022 Financial Results and Business Update Conference Call on February 16

07 фев 2023 07:00:01 Источник Nasdaq GlobeNewswire

Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Morgan Healthcare Conference

08 янв 2023 16:00:00 Источник Nasdaq GlobeNewswire

Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma’s TransCon™ PTH for Eligible U.S. Adult Patients with Hypoparathyroidism

04 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire

Ascendis Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 янв 2023 07:00:02 Источник Nasdaq GlobeNewswire

Ascendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult Patients with Hypoparathyroidism

05 дек 2022 07:00:00 Источник Nasdaq GlobeNewswire

Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference

22 ноя 2022 07:30:00 Источник Nasdaq GlobeNewswire

Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ PTH in Adult Patients with Hypoparathyroidism

14 ноя 2022 06:00:01 Источник Nasdaq GlobeNewswire

Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years

13 ноя 2022 17:15:00 Источник Nasdaq GlobeNewswire

Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022

11 ноя 2022 11:10:00 Источник Nasdaq GlobeNewswire

Ascendis Pharma Reports Third Quarter 2022 Financial Results

02 ноя 2022 15:01:00 Источник Nasdaq GlobeNewswire

FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism

31 окт 2022 07:00:01 Источник Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Third Quarter 2022 Financial Results and Business Update Conference Call on November 2

26 окт 2022 07:00:01 Источник Nasdaq GlobeNewswire